Search alternatives:
significant non » significant _ (Expand Search), significant amount (Expand Search), significant group (Expand Search)
gap increased » rate increased (Expand Search), care increased (Expand Search), gene increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
significant non » significant _ (Expand Search), significant amount (Expand Search), significant group (Expand Search)
gap increased » rate increased (Expand Search), care increased (Expand Search), gene increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
-
121
-
122
-
123
-
124
-
125
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, the respective treatment counts for anti-VEGF, STTA, MA-PC, PPV, and total treatments (mean ± standard deviation) in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”
-
126
-
127
-
128
GAP-43 immunoreactivity.
Published 2019“…The labeled GAP-43 bands were quantified. Note that the significant (*p<0.0001) increase in the GAP-43 expression is in the crush group compared to all groups at week 3 and week 6 post nerve injury. …”
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140